QR code

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds a...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Elio Gregory Pizzutilo, MD, Alberto Giuseppe Agostara, MD, Laura Roazzi, MD, Rebecca Romanò, MD, Valentina Motta, PhD, Calogero Lauricella, PhD, Giovanna Marrapese, PhD, Giulio Cerea, MD, Diego Signorelli, MD, PhD, Silvio Marco Veronese, PhD, Laura Giuseppina Giannetta, MD, Andrea Sartore-Bianchi, MD, Salvatore Siena, MD
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2023-11-01
Reeks:JTO Clinical and Research Reports
Onderwerpen:
Case report
Entrectinib
Repotrectinib
Resistance
ROS1 F2004V
Online toegang:http://www.sciencedirect.com/science/article/pii/S266636432300098X
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items